Lymphoid leukemia
Drug research and approvals for lymphoid leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 681 studies of lymphoid leukemia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 681
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That…NCT07948733 · Phase 1 · Cellogen Therapeutics Pvt. Ltd. · starts Oct 26, 2026
- Simulation-Free Single-Fraction Radiation Therapy for Indolent LymphomaNCT07945470 · Not applicable · University Health Network, Toronto · starts Oct 9, 2026
- A Personalised Anti-fatigue Program for Community-dwelling People With Chronic Lymphocytic LeukaemiaNCT07940920 · Not applicable · University of Surrey · starts Dec 1, 2026
- Impact of Vitamin D on Gut Microbiome and Metabolome Among Pediatric Oncology PatientsNCT07938333 · Not reported · Children's Hospital of Orange County · starts Nov 9, 2026
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute…NCT07936266 · Phase 1 · Sunil G. Iyer · starts Mar 31, 2027
- CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaNCT07927816 · Phase 1 · Liping Dou · starts Sep 1, 2026
- GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic LeukemiaNCT07910708 · Phase 1 · Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital · starts Aug 4, 2026
- Establishment of a Novel Flow Cytometric Diagnostic Assay to Effectively Evaluate Immune Reconstitution After…NCT07899840 · Not reported · Fondazione Matilde Tettamanti Menotti De Marchi Onlus · starts Feb 13, 2025
- Feasibility and Acceptability of Remote Saliva CollectionNCT07884474 · Not reported · St. Jude Children's Research Hospital · starts Dec 1, 2026
Approved 24 of 29
- RituximabB-cell chronic lymphocytic leukemia · B-lymphocyte antigen CD20 binding agent
- IbrutinibB-cell chronic lymphocytic leukemia · Tyrosine-protein kinase BTK inhibitor
- MethotrexatePrecursor cell lymphoblastic leukemia-lymphoma · Dihydrofolate reductase inhibitor
- VenetoclaxB-cell chronic lymphocytic leukemia · Apoptosis regulator Bcl-2 inhibitor
- CytarabinePrecursor cell lymphoblastic leukemia-lymphoma · DNA inhibitor
- ObinutuzumabB-cell chronic lymphocytic leukemia · B-lymphocyte antigen CD20 binding agent
- BendamustineB-cell chronic lymphocytic leukemia · DNA inhibitor
- MercaptopurinePrecursor cell lymphoblastic leukemia-lymphoma · Amidophosphoribosyltransferase inhibitor
- BlinatumomabPrecursor cell lymphoblastic leukemia-lymphoma · T cell surface glycoprotein CD3 cross-linking agent
- OfatumumabB-cell chronic lymphocytic leukemia · B-lymphocyte antigen CD20 binding agent
- AcalabrutinibB-cell chronic lymphocytic leukemia · Tyrosine-protein kinase BTK inhibitor
- AsparaginasePrecursor cell lymphoblastic leukemia-lymphoma · Asparagine hydrolytic enzyme
- AlemtuzumabB-cell chronic lymphocytic leukemia · CAMPATH-1 antigen inhibitor
- DasatinibPrecursor cell lymphoblastic leukemia-lymphoma · Tyrosine-protein kinase ABL inhibitor
- PegaspargasePrecursor cell lymphoblastic leukemia-lymphoma · Asparagine hydrolytic enzyme
- Inotuzumab ozogamicinPrecursor cell lymphoblastic leukemia-lymphoma · CD22 binding agent
- IdelalisibB-cell chronic lymphocytic leukemia · PI3-kinase p110-delta subunit inhibitor
- ClofarabinePrecursor cell lymphoblastic leukemia-lymphoma · Ribonucleoside-diphosphate reductase RR1 inhibitor
- ImatinibPrecursor cell lymphoblastic leukemia-lymphoma · Tyrosine-protein kinase ABL inhibitor
- Asparaginase erwinia chrysanthemiPrecursor cell lymphoblastic leukemia-lymphoma · Asparagine hydrolytic enzyme
- PonatinibPrecursor cell lymphoblastic leukemia-lymphoma · Bcr/Abl fusion protein inhibitor
- DuvelisibB-cell chronic lymphocytic leukemia · PI3-kinase p110-delta subunit inhibitor
- CrisantaspasePrecursor cell lymphoblastic leukemia-lymphoma · Asparagine hydrolytic enzyme
- Calaspargase pegolPrecursor cell lymphoblastic leukemia-lymphoma · Asparagine hydrolytic enzyme
Phase 3 12 of 51
- CyclophosphamideB-cell chronic lymphocytic leukemia · DNA inhibitor
- DexamethasonePrecursor cell lymphoblastic leukemia-lymphoma · Glucocorticoid receptor agonist
- LenalidomideB-cell chronic lymphocytic leukemia · CRL4(CRBN) E3 ubiquitin ligase inhibitor
- VincristinePrecursor cell lymphoblastic leukemia-lymphoma · Tubulin inhibitor
- FludarabineB-cell chronic lymphocytic leukemia
- DoxorubicinPrecursor cell lymphoblastic leukemia-lymphoma · DNA topoisomerase II alpha inhibitor
- PrednisonePrecursor cell lymphoblastic leukemia-lymphoma · Glucocorticoid receptor agonist
- UblituximabB-cell chronic lymphocytic leukemia · B-lymphocyte antigen CD20 binding agent
- ZanubrutinibB-cell chronic lymphocytic leukemia · Tyrosine-protein kinase BTK inhibitor
- LeucovorinPrecursor cell lymphoblastic leukemia-lymphoma
- FilgrastimPrecursor cell lymphoblastic leukemia-lymphoma · Granulocyte colony stimulating factor receptor agonist
- BortezomibPrecursor cell lymphoblastic leukemia-lymphoma · 26S proteasome inhibitor
Phase 2 12 of 125
- NavitoclaxB-cell chronic lymphocytic leukemia · Apoptosis regulator Bcl-2 inhibitor
- TacrolimusB-cell chronic lymphocytic leukemia · FK506-binding protein 1A inhibitor
- TafasitamabB-cell chronic lymphocytic leukemia · B-lymphocyte antigen CD19 binding agent
- ThalidomideB-cell chronic lymphocytic leukemia · CRL4(CRBN) E3 ubiquitin ligase inhibitor
- VorinostatPrecursor cell lymphoblastic leukemia-lymphoma · Histone deacetylase 1 inhibitor
- AlvocidibB-cell chronic lymphocytic leukemia · Cyclin-dependent kinase 2 inhibitor
- SirolimusPrecursor cell lymphoblastic leukemia-lymphoma · FK506-binding protein 1A inhibitor
- RuxolitinibPrecursor cell lymphoblastic leukemia-lymphoma · Tyrosine-protein kinase JAK1 inhibitor
- BevacizumabB-cell chronic lymphocytic leukemia · Vascular endothelial growth factor A inhibitor
- AzacitidinePrecursor cell lymphoblastic leukemia-lymphoma · DNA (cytosine-5)-methyltransferase 3A inhibitor
- EntospletinibB-cell chronic lymphocytic leukemia · Tyrosine-protein kinase SYK inhibitor
- LumiliximabB-cell chronic lymphocytic leukemia · Immunoglobulin epsilon Fc receptor antagonist
Phase 1 or earlier 12 of 150
- PalbociclibPrecursor cell lymphoblastic leukemia-lymphoma · CDK6/cyclin D1 inhibitor
- TanespimycinB-cell chronic lymphocytic leukemia · Heat shock protein HSP90 inhibitor
- MilatuzumabB-cell chronic lymphocytic leukemia · HLA-DR antigens-associated invariant chain antagonist
- BI-836826B-cell chronic lymphocytic leukemia · Leukocyte antigen CD37 inhibitor
- EverolimusPrecursor cell lymphoblastic leukemia-lymphoma · FK506-binding protein 1A inhibitor
- EpcoritamabB-cell chronic lymphocytic leukemia · B-lymphocyte antigen CD20 binding agent
- DecitabinePrecursor cell lymphoblastic leukemia-lymphoma · DNA (cytosine-5)-methyltransferase 3A inhibitor
- PlerixaforB-cell chronic lymphocytic leukemia · C-X-C chemokine receptor type 4 partial agonist
- IxazomibPrecursor cell lymphoblastic leukemia-lymphoma · 26S proteasome inhibitor
- ObatoclaxB-cell chronic lymphocytic leukemia · Apoptosis regulator Bcl-2 inhibitor
- OtlertuzumabB-cell chronic lymphocytic leukemia · Leukocyte antigen CD37 binding agent
- RimiducidPrecursor cell lymphoblastic leukemia-lymphoma
How its trials ended
2,319 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 696 whose ending is known, 37% met their primary endpoint, 4% missed it and 60% stopped early.
- Completed, result not reported73232%
- Ongoing66929%
- Met its primary endpoint25511%
- Status unknown22210%
- Stopped: other or unclear2169%
- Stopped: enrollment or feasibility974%
- Stopped: sponsor or business decision532%
- Missed its primary endpoint251%
- Stopped: lack of efficacy251%
- Stopped: funding161%
- Stopped: safety9<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA